Simvastatin Plus Dual Anti-HER2 Therapy for Metastatic Breast Cancer
Status:
Recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
This study recruits patients with metastatic breast cancer who have progressed on their
current regimen of dual anti-HER2 therapy. This study evaluates whether or not the addition
of simvastatin to the dual anti-HER2 therapy regimen helps make the tumor respond to the
anti-HER2 therapy again. All participants will receive simvastatin in combination with their
current anti-HER2 therapy regimen.